Overview
Hepatitis C virus (HCV) infection is one of the most common causes of chronic liver disease, accounting for nearly 60–70% of all chronic hepatitis cases worldwide. Acute HCV infection is often asymptomatic or associated with non-specific symptoms and therefore frequently remains undiagnosed. However, a significant proportion of infected individuals, approximately 60–85%, progress to chronic infection, which increases the risk of cirrhosis, end-stage liver disease, and hepatocellular carcinoma.
HCV is an RNA virus with marked genetic diversity. Due to rapid viral replication and transcriptional variations, the virus continuously evolves, resulting in differences in disease progression and therapeutic response across geographical regions. Based on genetic sequence variation, HCV is classified into six major genotypes (1 to 6), each with multiple subtypes. In India, genotype 3 is the most prevalent, followed by genotype 1, while genotypes 4 and 6 show increased prevalence in certain regions.
HCV genotyping is an important molecular tool used alongside HCV RNA detection and viral load estimation. It plays a crucial role in guiding antiviral therapy, predicting treatment response, and understanding epidemiological patterns of infection. HCV – GENOTYPING
Symptoms
HCV infection often remains clinically silent, especially during the early or acute phase. Many patients do not show noticeable symptoms and are diagnosed incidentally during routine investigations or screening.
When symptoms occur, they are related to liver inflammation and may include fatigue, fever, loss of appetite, nausea, abdominal discomfort, and jaundice. In chronic infection, symptoms may remain minimal even as liver damage progresses, making laboratory testing, including genotyping, essential for disease assessment.
Causes
HCV infection is transmitted primarily through exposure to infected blood or blood products. Common routes include blood transfusions, sharing of needles or injection equipment, and unsafe medical practices.
Healthcare workers exposed to blood and body fluids are also at risk. Vertical transmission from mother to child may occur, although less commonly. There is currently no vaccine available for hepatitis C, making early detection and molecular characterization of the virus critical for disease control.
Risk Factors
Individuals with a history of blood transfusions, injection drug use, or needle sharing are at increased risk of acquiring HCV infection. Newborns of HCV-infected mothers and immunocompromised individuals are also considered high-risk groups.
Genotype-specific factors influence disease progression and response to therapy. Certain genotypes are associated with more aggressive disease, delayed viral clearance, or increased risk of cirrhosis and hepatocellular carcinoma. For example, genotype 3 has been linked to higher rates of liver steatosis and disease progression. Mixed genotype infections may also occur, particularly in regions with diverse circulating strains, complicating diagnosis and treatment planning.
Prevention
Prevention of HCV infection relies on early diagnosis, screening of high-risk populations, and safe medical practices, as no vaccine is currently available. Proper screening of blood products, avoidance of needle sharing, and adherence to infection control measures in healthcare settings are essential preventive strategies.
HCV genotyping contributes to prevention efforts by guiding individualized treatment strategies and improving treatment success rates. By identifying genotypes prone to resistance or poor response, clinicians can optimize antiviral therapy and reduce long-term complications.
Clinical and Diagnostic Importance
HCV genotyping has significant clinical relevance. It helps determine the choice of antiviral therapy, predict treatment duration, and assess the likelihood of treatment response. Certain genotypes respond better to specific antiviral regimens, while others may require longer or alternative treatment strategies.
Genotyping is also valuable for monitoring disease progression, evaluating treatment failure or relapse, and differentiating between reinfection and recurrence after therapy. In addition, it supports epidemiological studies by tracking transmission patterns and the geographic distribution of HCV strains.
Despite its advantages, genotyping has limitations. It is costly, requires specialized equipment and trained personnel, and may produce false-negative or false-positive results in cases of low viral load. Highly diverse or rapidly evolving viral strains may not always be captured by standard assays. Mixed genotype infections can further complicate interpretation, particularly when viral concentrations are similar.
Overall, HCV genotyping is an essential component of comprehensive hepatitis C management. When combined with viral load testing and clinical evaluation, it enables personalized treatment, improves prognosis, and supports public health efforts to control HCV infection.
